Paritaprevir

Overview

Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC 50 s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC 50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor).

Application

Products | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Infection | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Viral Infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > HCV Protease | Products > Signaling Pathways > HCV | Products > Signaling Pathways > SARS-CoV

Product Information

• Catalog No.: HY-12594
• CAS No.: 1216941-48-8
• Molecular Formula: C40H43N7O7S
• Molecular Weight: 765.88
• Purity: 99.84%
• Storage: 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Solubility: ≥ 2.08 mg/mL (2.72 mM); Clear solution
• Availability: In-stock

Source

Original product source